Nocturnal Hypoglycemia and Morning Hyperglycemia Management

Primary Mechanism: Dawn Phenomenon

The American Diabetes Association notes that the dawn phenomenon represents a physiologic rise in glucose during the early morning hours (typically 3 AM to 7 AM) due to increased hepatic glucose production driven by counterregulatory hormones (growth hormone, cortisol) that naturally surge in the early morning 2
The dawn phenomenon occurs independently of nocturnal hypoglycemia and is a normal physiologic process that becomes problematic when basal insulin coverage is insufficient, as stated by the American Association of Clinical Endocrinologists 1, 2
The waning insulin effect from basal insulin given the previous evening, particularly with shorter-duration rapid-acting analogs, contributes to the dawn phenomenon, according to the Endocrine Society 1

To distinguish between the dawn phenomenon and the Somogyi effect, checking a 3 AM glucose level is recommended: if 3 AM glucose is low (<70 mg/dL) with high morning glucose, this suggests nocturnal hypoglycemia, but the morning hyperglycemia is more likely due to overbasalization rather than true Somogyi effect, as suggested by the American Diabetes Association 2, 3
If 3 AM glucose is normal/elevated with high morning glucose, this indicates classic dawn phenomenon requiring increased basal insulin coverage during early morning hours, according to the European Association for the Study of Diabetes 1, 2

A bedtime-to-morning glucose differential ≥50 mg/dL (≥2.8 mmol/L) signals overbasalization, using excessive basal insulin that masks insufficient mealtime insulin coverage, as noted by the American Association of Clinical Endocrinologists 2, 3
Clinical signs of overbasalization include nocturnal hypoglycemia (aware or unaware), high glucose variability, and large preprandial-to-postprandial glucose differentials, according to the Endocrine Society 3

For nocturnal hypoglycemia prevention, switching to longer-acting basal analogs (U-300 glargine or degludec) which convey lower nocturnal hypoglycemia risk than U-100 glargine or NPH insulin is recommended, as stated by the American Diabetes Association 3, 4
Implementing automated insulin delivery (AID) systems with continuous glucose monitoring (CGM) and predictive low-glucose suspension features significantly reduces nocturnal hypoglycemia while maintaining glycemic control, according to the European Association for the Study of Diabetes 1, 4
For dawn phenomenon management, increasing basal insulin coverage during early morning hours using insulin pump therapy that allows time-specific basal rate adjustments is recommended, as suggested by the American Association of Clinical Endocrinologists 1, 2

Patients with any symptomatic evidence of nighttime hypoglycemia should test glucose in the middle of the night (2-3 AM) and make appropriate treatment adjustments, as recommended by the American Medical Association 5
Continuous glucose monitoring (CGM) with alarms set for low glucose provides superior detection and prevention of nocturnal hypoglycemia compared to fingerstick monitoring alone, according to the Endocrine Society 4